News

Stocktwits on MSN7h
Johnson & Johnson Submits Supplemental Drug Application To FDA For Schizophrenia Drug Caplyta
Johnson & Johnson (JNJ) said on Tuesday that it has submitted a supplemental new drug application to the U.S. Food and Drug ...
Food Dyes Are Lurking in Surprising Places
In addition to finding these dyes in brightly colored processed foods, the researchers also found them in more muted foods ...
Wegovy and Zepbound prices fall, but access to the obesity drugs still isn’t guaranteed
Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...
Kennedy’s Battle Against Food Dyes Hits a Roadblock: M&M’s
The health secretary has used peer pressure to persuade food makers to nix synthetic dyes. The candy industry is holding out, ...
I Write About Food Recalls for a Living—Here's How to Find the Most Important Information on Your Product
In recalls, best-by or use-by dates are commonly provided. Even if the affected date has passed, be sure to check your ...
STAT1d
Inside the staff exodus and tanking morale that threaten Makary’s FDA
WASHINGTON — The steady erosion of experienced staff at the Food and Drug Administration is slowly compromising the agency’s ...
U.S. FDA Grants Orphan Drug Designation to Adcentrx Therapeutics' ADRX-0405 STEAP1 ADC for Gastric Cancer
Adcentrx Therapeutics ("Adcentrx"), a clinical-stage biotechnology company redefining Antibody-Drug Conjugate (ADC) therapies for cancer treatment and other life-threatening diseases, today announced ...
After delay, Kalvista wins FDA OK for drug to treat rare swelling disorder
The company had blamed FDA "resource constraints" for the delay, while a rival drug for hereditary angioedema received an ...
US FDA Approves KalVista's Oral Swelling Disorder Drug, Shares Rise
(Reuters) -KalVista Pharmaceuticals said on Monday the U.S. Food and Drug Administration has approved its drug, the first ...
ALS News Today1d
FDA grants orphan drug status to ALS gene therapy SNUG01
The FDA granted orphan drug designation to Sineugene Therapeutics' SNUG01, a first-in-class experimental gene therapy for ...